Zymeworks (ZYME) Stock Forecast, Price Target & Predictions

OverviewRevenue Ownership Financials Chart Transcripts

ZYME Stock Forecast

Zymeworks stock forecast is as follows: an average price target of $15.75 (represents a 6.64% upside from ZYME’s last price of $14.77) and a rating consensus of 'Buy', based on 7 wall street analysts offering a 1-year stock forecast.

ZYME Price Target

The average price target for Zymeworks (ZYME) is $15.75 based on 1-year price targets from 7 Wall Street analysts in the past 3 months, with a price target range of $28.00 to $11.00. This represents a potential 6.64% upside from ZYME's last price of $14.77.

ZYME Analyst Ratings

Buy

According to 7 Wall Street analysts, Zymeworks's rating consensus is 'Buy'. The analyst rating breakdown for ZYME stock is 0 'Strong Buy' (0.00%), 5 'Buy' (71.43%), 2 'Hold' (28.57%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).

Zymeworks Price Target by Analyst

Date	Analyst	Company	Price Target	Price when Published	Price Target/Price when Published	Price Target/Last Closing Price
Nov 01, 2024	Derek Archila	Wells Fargo	$12.00	$13.28	-9.64%	-18.75%
Oct 28, 2024	Stephen Willey	Stifel Nicolaus	$28.00	$13.11	113.58%	89.57%
Sep 25, 2024	Robert Burns	H.C. Wainwright	$12.00	$12.50	-4.00%	-18.75%
Sep 18, 2024	Andrew Berens	H.C. Wainwright	$10.00	$12.30	-18.70%	-32.30%
Sep 10, 2024	Stephen Willey	Stifel Nicolaus	$21.00	$11.75	78.72%	42.18%
Dec 19, 2022	Akash Tewari	Jefferies	$11.00	$6.79	62.00%	-25.52%
Nov 01, 2022	Robert Burns	H.C. Wainwright	$8.00	$7.29	9.66%	-45.84%
Sep 20, 2021	Robert Burns	H.C. Wainwright	$44.00	$33.07	33.05%	197.90%

Row per page

Go to

The latest Zymeworks stock forecast, released on Nov 01, 2024 by Derek Archila from Wells Fargo, set a price target of $12.00, which represents a -9.64% decrease from the stock price at the time of the forecast ($13.28), and a -18.75% decrease from ZYME last price ($14.77).

Zymeworks Price Target by Period

	1M	3M	12M
# Anlaysts	2	5	5
Avg Price Target	$20.00	$16.60	$16.60
Last Closing Price	$14.77	$14.77	$14.77
Upside/Downside	35.41%	12.39%	12.39%

In the current month, the average price target of Zymeworks stock is $20.00, according to 2 Wall Street analysts offering twelve months forecast. The average price target represents a 35.41% increase as opposed to Zymeworks's last price of $14.77. This month's average price target is up 20.48% compared to last quarter, and up 20.48% compared to last year.

Analyst Ratings Upgrades/Downgrades

Date	Company	Previous Rating	New Rating	Rating Change
Nov 07, 2024	Leerink Partners	-	Outperform	Upgrade
Oct 22, 2024	H.C. Wainwright	Buy	Buy	Hold
Oct 22, 2024	H.C. Wainwright	Neutral	Neutral	Hold
Sep 18, 2024	H.C. Wainwright	Neutral	Neutral	Hold
Jun 06, 2024	Wells Fargo	Buy	Buy	Hold
May 07, 2024	Wells Fargo	Buy	Buy	Hold
May 07, 2024	H.C. Wainwright	Underperform	Underperform	Hold
Dec 22, 2022	Barclays	Equal-Weight	Equal-Weight	Hold
Dec 19, 2022	Jefferies	-	Buy	Upgrade
Oct 21, 2022	SVB Leerink	-	Market Perform	Downgrade

Row per page

Go to

Zymeworks's last stock rating was published by Leerink Partners on Nov 07, 2024. The company Upgrade its ZYME rating from "null" to "Outperform".

Zymeworks Financial Forecast

Zymeworks Revenue Forecast

	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20	Jun 20	Mar 20	Dec 19	Sep 19	Jun 19	Mar 19	Mar 18	Mar 17
Revenue	-	-	-	-	-	-	-	-	-	-	-	$35.58M	$402.49M	$2.63M	$5.44M	$1.92M	$19.87M	$4.39M	$1.77M	$644.00K	$15.68M	$2.64M	$12.36M	$8.27M	$1.88M	$7.86M	$7.88M	$11.93M	$40.00K	$230.00K
Avg Forecast	$18.20M	$18.00M	$17.90M	$17.70M	$54.05M	$17.90M	$11.94M	$17.52M	$17.66M	$14.63M	$17.00M	$19.43M	$214.37M	$3.94M	$7.09M	$4.01M	$10.65M	$8.58M	$8.11M	$7.11M	$10.30M	$12.72M	$8.11M	$6.75M	$9.48M	$7.11M	$5.10M	$6.88M	$1.00M	$210.51K
High Forecast	$34.80M	$34.42M	$34.23M	$21.37M	$130.37M	$34.23M	$11.94M	$17.52M	$24.12M	$14.77M	$32.51M	$37.16M	$409.94M	$3.94M	$7.09M	$4.01M	$10.65M	$8.58M	$8.11M	$7.11M	$10.30M	$12.72M	$8.11M	$6.75M	$9.48M	$7.11M	$5.10M	$6.88M	$1.20M	$252.61K
Low Forecast	$6.53M	$6.46M	$6.43M	$14.03M	$9.51M	$6.43M	$11.94M	$17.52M	$14.46M	$14.50M	$6.10M	$6.98M	$76.95M	$3.94M	$7.09M	$4.01M	$10.65M	$8.58M	$8.11M	$7.11M	$10.30M	$12.72M	$8.11M	$6.75M	$9.48M	$7.11M	$5.10M	$6.88M	$800.00K	$168.41K
# Analysts	1	1	1	1	5	4	4	4	5	4	4	4	3	3	3	3	4	4	4	4	5	4	5	4	4	3	4	3	8	16
Surprise %	-	-	-	-	-	-	-	-	-	-	-	1.83%	1.88%	0.67%	0.77%	0.48%	1.86%	0.51%	0.22%	0.09%	1.52%	0.21%	1.52%	1.22%	0.20%	1.11%	1.55%	1.73%	0.04%	1.09%

Zymeworks's average Quarter revenue forecast for Jun 23 based on 4 analysts is $17.00M, with a low forecast of $6.10M, and a high forecast of $32.51M. ZYME's average Quarter revenue forecast represents a -52.22% decrease compared to the company's last Quarter revenue of $35.58M (Mar 23).

Zymeworks EBITDA Forecast

	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20	Jun 20	Mar 20	Dec 19	Sep 19	Jun 19	Mar 19	Mar 18	Mar 17
# Analysts	1	1	1	1	5	4	4	4	5	4	4	4	3	3	3	3	4	4	4	4	5	4	5	4	4	3	4	3	8	16
EBITDA	-	-	-	-	-	-	-	-	-	$-33.24B	$-54.11M	$-27.28M	$319.39M	$-49.62M	$-63.65M	$-66.99M	$-38.78M	$-56.71M	$-64.61M	$-40.70M	$-34.17M	$-68.63M	$-35.26M	$-26.07M	$-68.62M	$-29.66M	$-26.79M	$-11.95M	$-20.54M	$-15.11M
Avg Forecast	$-13.26M	$-13.11M	$-13.04M	$-12.90M	$-39.38M	$-13.04M	$-8.70M	$-64.18M	$-12.87M	$-10.66M	$-12.39M	$-58.35M	$-73.54M	$-2.90M	$-5.22M	$-53.04M	$-7.85M	$-6.32M	$-5.98M	$-48.22M	$-7.59M	$-9.37M	$-5.98M	$-36.30M	$-6.98M	$-5.23M	$-3.76M	$-14.02M	$-16.73M	$-13.83M
High Forecast	$-4.76M	$-4.71M	$-4.68M	$-10.22M	$-6.93M	$-4.68M	$-8.70M	$-51.34M	$-10.54M	$-10.57M	$-4.45M	$-46.68M	$-58.83M	$-2.90M	$-5.22M	$-42.43M	$-7.85M	$-6.32M	$-5.98M	$-38.58M	$-7.59M	$-9.37M	$-5.98M	$-29.04M	$-6.98M	$-5.23M	$-3.76M	$-11.22M	$-13.38M	$-11.06M
Low Forecast	$-25.36M	$-25.08M	$-24.94M	$-15.57M	$-94.99M	$-24.94M	$-8.70M	$-77.02M	$-17.58M	$-10.76M	$-23.69M	$-70.01M	$-88.24M	$-2.90M	$-5.22M	$-63.65M	$-7.85M	$-6.32M	$-5.98M	$-57.86M	$-7.59M	$-9.37M	$-5.98M	$-43.56M	$-6.98M	$-5.23M	$-3.76M	$-16.82M	$-20.07M	$-16.60M
Surprise %	-	-	-	-	-	-	-	-	-	3117.29%	4.37%	0.47%	-4.34%	17.11%	12.19%	1.26%	4.94%	8.97%	10.81%	0.84%	4.50%	7.32%	5.90%	0.72%	9.83%	5.67%	7.13%	0.85%	1.23%	1.09%

4 analysts predict ZYME's average Quarter EBITDA for Mar 23 to be $-58.35M, with a high of $-46.68M and a low of $-70.01M. This is -118.27% lower than Zymeworks's previous annual EBITDA (Dec 22) of $319.39M.

Zymeworks Net Income Forecast

	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20	Jun 20	Mar 20	Dec 19	Sep 19	Jun 19	Mar 19	Mar 18	Mar 17
# Analysts	1	1	1	1	5	4	4	4	5	4	4	4	3	3	3	3	4	4	4	4	5	4	5	4	4	3	4	3	8	16
Net Income	-	-	-	-	-	-	-	-	-	$-28.69B	$-51.15M	$-24.35M	$309.43M	$-47.85M	$-64.62M	$-72.63M	$-39.15M	$-60.58M	$-67.52M	$-44.59M	$-37.89M	$-72.56M	$-38.96M	$-31.14M	$-72.24M	$-30.48M	$-29.08M	$-13.64M	$-21.20M	$-15.93M
Avg Forecast	$-35.79M	$-34.27M	$-31.99M	$-29.70M	$721.28K	$-30.22M	$-31.80M	$-69.05M	$-31.58M	$-35.75M	$-35.82M	$-62.77M	$-73.09M	$-71.70M	$-72.91M	$-57.07M	$-87.18M	$-96.42M	$-80.29M	$-51.88M	$-93.66M	$-67.68M	$-65.65M	$-40.45M	$-64.95M	$-55.51M	$-48.65M	$-16.00M	$-17.27M	$-14.58M
High Forecast	$-5.97M	$-5.71M	$-5.33M	$-21.32M	$7.83M	$-5.04M	$-5.30M	$-55.24M	$-18.63M	$-5.96M	$-5.97M	$-50.22M	$-58.47M	$-71.70M	$-72.91M	$-45.65M	$-87.18M	$-96.42M	$-80.29M	$-41.50M	$-93.66M	$-67.68M	$-65.65M	$-32.36M	$-64.95M	$-55.51M	$-48.65M	$-12.80M	$-13.81M	$-11.66M
Low Forecast	$-78.25M	$-74.92M	$-69.92M	$-38.08M	$-5.15M	$-66.06M	$-69.51M	$-82.86M	$-46.16M	$-78.14M	$-78.30M	$-75.33M	$-87.70M	$-71.70M	$-72.91M	$-68.48M	$-87.18M	$-96.42M	$-80.29M	$-62.25M	$-93.66M	$-67.68M	$-65.65M	$-48.54M	$-64.95M	$-55.51M	$-48.65M	$-19.20M	$-20.72M	$-17.49M
Surprise %	-	-	-	-	-	-	-	-	-	802.54%	1.43%	0.39%	-4.23%	0.67%	0.89%	1.27%	0.45%	0.63%	0.84%	0.86%	0.40%	1.07%	0.59%	0.77%	1.11%	0.55%	0.60%	0.85%	1.23%	1.09%

Zymeworks's average Quarter net income forecast for Mar 23 is $-62.77M, with a range of $-75.33M to $-50.22M. ZYME's average Quarter net income forecast represents a -120.29% decrease compared to the company's last Quarter net income of $309.43M (Dec 22).

Zymeworks SG&A Forecast

	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20	Jun 20	Mar 20	Dec 19	Sep 19	Jun 19	Mar 19	Mar 18	Mar 17
# Analysts	1	1	1	1	5	4	4	4	5	4	4	4	3	3	3	3	4	4	4	4	5	4	5	4	4	3	4	3	8	16
SG&A	-	-	-	-	-	-	-	-	-	$16.97B	$21.71M	$16.95M	$30.13M	$15.89M	$15.24M	$12.09M	$5.89M	$15.47M	$19.95M	$1.30M	$13.96M	$22.81M	$13.49M	$7.62M	$30.24M	$12.17M	$12.76M	$9.00M	$7.07M	$6.26M
Avg Forecast	$23.14M	$22.89M	$22.76M	$22.51M	$68.73M	$22.76M	$15.18M	$2.01M	$22.46M	$18.61M	$21.62M	$1.82M	$10.99M	$5.01M	$9.01M	$1.66M	$13.55M	$10.91M	$10.32M	$1.51M	$13.10M	$16.18M	$10.32M	$8.59M	$12.05M	$9.03M	$6.48M	$8.74M	$1.27M	$267.67K
High Forecast	$44.25M	$43.77M	$43.52M	$27.17M	$165.77M	$43.53M	$15.18M	$2.41M	$30.67M	$18.78M	$41.34M	$2.19M	$13.19M	$5.01M	$9.01M	$1.99M	$13.55M	$10.91M	$10.32M	$1.81M	$13.10M	$16.18M	$10.32M	$8.59M	$12.05M	$9.03M	$6.48M	$8.74M	$1.53M	$321.20K
Low Forecast	$8.31M	$8.22M	$8.17M	$17.84M	$12.09M	$8.17M	$15.18M	$1.61M	$18.39M	$18.44M	$7.76M	$1.46M	$8.79M	$5.01M	$9.01M	$1.33M	$13.55M	$10.91M	$10.32M	$1.21M	$13.10M	$16.18M	$10.32M	$8.59M	$12.05M	$9.03M	$6.48M	$8.74M	$1.02M	$214.13K
Surprise %	-	-	-	-	-	-	-	-	-	911.92%	1.00%	9.29%	2.74%	3.17%	1.69%	7.29%	0.44%	1.42%	1.93%	0.86%	1.07%	1.41%	1.31%	0.89%	2.51%	1.35%	1.97%	1.03%	5.56%	23.38%

Zymeworks's average Quarter SG&A projection for Dec 23 is $22.46M, based on 5 Wall Street analysts, with a range of $18.39M to $30.67M. The forecast indicates a -99.87% fall compared to ZYME last annual SG&A of $16.97B (Sep 23).

Zymeworks EPS Forecast

	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20	Jun 20	Mar 20	Dec 19	Sep 19	Jun 19	Mar 19	Mar 18	Mar 17
# Analysts	1	1	1	1	5	4	4	4	5	4	4	4	3	3	3	3	4	4	4	4	5	4	5	4	4	3	4	3	8	16
EPS	-	-	-	-	-	-	-	-	-	$-0.00	$-0.00	$-0.36	$4.65	$-0.72	$-0.97	$-1.18	$-0.76	$-1.17	$-1.31	$-0.87	$-0.74	$-1.43	$-0.77	$-0.64	$-1.66	$-0.70	$-0.89	$-0.43	$-0.83	$-0.81
Avg Forecast	$-0.47	$-0.45	$-0.42	$-0.39	$0.01	$-0.40	$-0.42	$-0.32	$-0.41	$-0.47	$-0.47	$-0.54	$1.43	$-0.94	$-0.95	$-0.98	$-1.14	$-1.26	$-1.05	$-1.04	$-1.23	$-0.89	$-0.86	$-1.15	$-0.85	$-0.73	$-0.64	$-0.52	$-0.57	$-0.54
High Forecast	$-0.08	$-0.08	$-0.07	$-0.28	$0.10	$-0.07	$-0.07	$-0.05	$-0.24	$-0.08	$-0.08	$-0.09	$3.12	$-0.94	$-0.95	$-0.98	$-1.14	$-1.26	$-1.05	$-1.04	$-1.23	$-0.89	$-0.86	$-1.15	$-0.85	$-0.73	$-0.64	$-0.52	$-0.46	$-0.43
Low Forecast	$-1.03	$-0.98	$-0.92	$-0.50	$-0.07	$-0.87	$-0.91	$-0.70	$-0.61	$-1.03	$-1.03	$-1.17	$0.24	$-0.94	$-0.95	$-0.98	$-1.14	$-1.26	$-1.05	$-1.04	$-1.23	$-0.89	$-0.86	$-1.15	$-0.85	$-0.73	$-0.64	$-0.52	$-0.68	$-0.65
Surprise %	-	-	-	-	-	-	-	-	-	0.00%	0.00%	0.67%	3.26%	0.77%	1.02%	1.20%	0.67%	0.93%	1.25%	0.83%	0.60%	1.61%	0.90%	0.56%	1.95%	0.96%	1.40%	0.82%	1.46%	1.50%

According to 4 Wall Street analysts, Zymeworks's projected average Quarter EPS for Mar 23 is $-0.54, with a low estimate of $-1.17 and a high estimate of $-0.09. This represents a -111.53% decrease compared to ZYME previous annual EPS of $4.65 (Dec 22).

Zymeworks Peer Comparison by Price Target

Ticker	Company	Last Closing Price	Avg Price Target	Upside/Downside	Avg Rating
BLUE	bluebird bio	$0.31	$14.13	4458.06%	Hold
ZNTL	Zentalis Pharmaceuticals	$2.99	$21.86	631.10%	Buy
CABA	Cabaletta Bio	$2.54	$16.33	542.91%	Buy
INZY	Inozyme Pharma	$2.81	$14.67	422.06%	Buy
EDIT	Editas Medicine	$2.48	$12.85	418.15%	Buy
RLAY	Relay Therapeutics	$4.80	$19.40	304.17%	Buy
DAWN	Day One Biopharmaceuticals	$13.52	$38.80	186.98%	Buy
STOK	Stoke Therapeutics	$11.61	$30.60	163.57%	Buy
APLS	Apellis Pharmaceuticals	$28.99	$74.50	156.99%	Buy
ANNX	Annexon	$5.46	$14.00	156.41%	Buy
ARWR	Arrowhead Pharmaceuticals	$18.60	$45.38	143.98%	Buy
TERN	Terns Pharmaceuticals	$5.91	$14.25	141.12%	Buy
SNDX	Syndax Pharmaceuticals	$15.77	$34.30	117.50%	Buy
YMAB	Y-mAbs Therapeutics	$10.86	$20.00	84.16%	Buy
CYTK	Cytokinetics	$51.09	$83.23	62.91%	Buy
AKRO	Akero Therapeutics	$31.03	$46.00	48.24%	Buy
MRSN	Mersana Therapeutics	$2.22	$3.00	35.14%	Buy
PTGX	Protagonist Therapeutics	$38.65	$50.00	29.37%	Buy
TVTX	Travere Therapeutics	$17.39	$21.75	25.07%	Buy
BPMC	Blueprint Medicines	$94.60	$109.71	15.97%	Buy
RVMD	Revolution Medicines, Inc. Warrant	$56.47	$60.63	7.37%	Buy
ZYME	Zymeworks	$14.77	$15.75	6.64%	Buy
ALEC	Alector	$3.85	$4.00	3.90%	Buy
PRQR	ProQR Therapeutics	$3.60	$3.63	0.83%	Buy

ZYME Forecast FAQ

Is Zymeworks a good buy?

Yes, according to 7 Wall Street analysts, Zymeworks (ZYME) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 5 'Buy' recommendations, accounting for 71.43% of ZYME's total ratings.

What is ZYME's price target?

Zymeworks (ZYME) average price target is $15.75 with a range of $11 to $28, implying a 6.64% from its last price of $14.77. The data is based on 7 Wall Street analysts who provided a twelve-month price target estimate in the last three months.

Will Zymeworks stock go up soon?

According to Wall Street analysts' prediction for ZYME stock, the company can go up by 6.64% (from the last price of $14.77 to the average price target of $15.75), up by 89.57% based on the highest stock price target, and down by -25.52% based on the lowest stock price target.

Can Zymeworks stock reach $20?

ZYME's highest twelve months analyst stock price target of $28 supports the claim that Zymeworks can reach $20 in the near future.

What is Zymeworks's current price target trend?

2 Wall Street analysts forecast a $20 price target for Zymeworks (ZYME) this month, up 35.41% from its last price of $14.77. Compared to the last 3 and 12 months, the average price target increased by 12.39% and increased by 12.39%, respectively.

What are Zymeworks's analysts' financial forecasts?

Zymeworks's analysts financial forecasts for the fiscal year (Dec 2024) are as follows: average revenue is $101.41M (high $194.06M, low $45.39M), average EBITDA is $-125M (high $-71.65M, low $-206M), average net income is $-130M (high $-57.746M, low $-224M), average SG&A $108.68M (high $226.88M, low $37.04M), and average EPS is $-1.127 (high $-0.0866, low $-2.552). ZYME's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $71.8M (high $124.82M, low $33.45M), average EBITDA is $-52.314M (high $-24.375M, low $-90.947M), average net income is $-132M (high $-38.334M, low $-261M), average SG&A $91.3M (high $158.71M, low $42.54M), and average EPS is $-1.73 (high $-0.503, low $-3.429).

Did the ZYME's actual financial results beat the analysts' financial forecasts?

Based on Zymeworks's last annual report (Dec 2022), the company's revenue was $412.48M, beating the average analysts forecast of $229.4M by 79.81%. Apple's EBITDA was $130.53M, missing the average prediction of $-135M by -196.90%. The company's net income was $124.34M, missing the average estimation of $-275M by -145.25%. Apple's SG&A was $73.36M, beating the average forecast of $26.67M by 175.06%. Lastly, the company's EPS was $1.91, missing the average prediction of $-1.449 by -231.84%. In terms of the last quarterly report (Mar 2023), Zymeworks's revenue was $35.58M, beating the average analysts' forecast of $19.43M by 83.07%. The company's EBITDA was $-27.281M, missing the average prediction of $-58.346M by -53.24%. Zymeworks's net income was $-24.353M, missing the average estimation of $-62.773M by -61.20%. The company's SG&A was $16.95M, beating the average forecast of $1.82M by 828.86%. Lastly, the company's EPS was $-0.36, missing the average prediction of $-0.536 by -32.85%